期刊文献+

单剂量口服奥美沙坦酯片在中国健康志愿者体内的药代动力学研究 被引量:1

Pharmacokinetic Study of Olmesartan Medoxomil Tablets on Chinese Healthy Volunteers in Vivo after Single Dose Orally
下载PDF
导出
摘要 目的 研究奥美沙坦酯片单剂量口服给药在中国健康志愿者体内的药代动力学特征.方法 29名健康志愿者完成本次试验,随机分为低剂量组10名、中剂量组10名和高剂量组9名,分别单剂量口服奥美沙坦酯片20、40和80 mg,采用高效液相-质谱法测定不同时间血浆中奥美沙坦浓度,以药代动力学软件DAS Ver 2.0计算药代动力学参数.结果 奥美沙坦在体内过程符合二房室模型.血药浓度峰值和曲线下面积与剂量呈正相关(r=0.80,r=0.87,P〈0.01),3个剂量组达峰时间、半衰期和平均驻留时间比较差异均无统计学意义(P〉0.05),高剂量组表观清除率均高于低、中剂量组(P〈0.05).结论 奥美沙坦酯片20~80 mg单剂量口服给药时在中国健康志愿者体内表现出良好的线性关系,安全性好. Objective To study the pharmacokinetic characteristics of olmesartan medoxomil tablets on Chinese healthy volunteers in vivo after single dose orally. Methods Twenty-nine healthy volunteers were randomly divided into low-dose group (n = 10) , middle-dose group (n = 10) and high-dose group (n = 9) with Olmesartan medoxomil tablets 20, 40 and 80 mg of oral dose for one time respectively. Plasma concentrations of olmesartan at different times were determined with high performance liquid chromatography-mass spectrography (HPLC-MS) method, and the pharmacokinetic parameters were calculated by DAS Ver 2. 0 software. Results The physiological dispositions of olmesartan were fitted in to a two-compartment model in vivo. Plasma drug level peaks and area under curve had a positive correlation with doses ( r = 0. 80 .r = 0. 87 ,P 〈 0. 01 ) , there were no significant differences in peak reach time, half life period and mean residence time among the three groups (P 〉 0.05) , and the aparent clearance of high-dose group was higher than those of low and medium dose groups (P 〈 0. 05). Conclusion Satisfactory linear pharmacokinetic characteristics can be achieved by Olmesartan medoxomil tablets of 20 - 80 mg single dose orally in vivo of Chinese health volunteers.
出处 《解放军医药杂志》 CAS 2014年第1期67-69,共3页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金 国家科技部"十二五重大新药创制"科技重大专项(2011ZXJ09202-12)
关键词 奥美沙坦酯片 高效液相色谱 质谱法 血药浓度 药代动力学 Olmesartan medoxomil tablet High performance liquid chromatography Mass spectrography Plasma concentration Pharmacokinetics
  • 相关文献

参考文献16

二级参考文献30

共引文献25

同被引文献22

  • 1Yamada A, Maeda K, Kamiyama E,et d.Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan,a selective antagonist of the angiotensin Ⅱ ATl-receptor[J].Drug Metab Dispos,2007,35(12):2166-2176.
  • 2Wehling M.Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?[J].Clin Ther,2004,26 (Suppl A): A21-A27.
  • 3Chrysant SG, Dimas B, Shiraz M.Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update[J].J Hum Hypertens, 2007,21 (9) : 699- 708.
  • 4Kreutz R, Bolbrinker J, Huber M. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combina- tion in healthy subjects [J].Clin Drug Investig,2006,26 ( 1 ) : 29-34.
  • 5Huber M,Bolbrinker J,Kreutz R.Pharmacokinetics and safe- ty of olmesartan medoxomil in combination with gliben- clamide in healthy volunteers[J].Clin Exp Hypertens,2006, 28(7) :631-643.
  • 6Yoshihara K ,Gao Y ,Shiga H ,et d.Population pharma- cokinetics of olmesartan following oral administration of its prodrug,olmesartan medoxomil: in healthy volunteers and hypertensive patients[J].Clin Pharmacokinet,2005,44 (12) : 1329-1342.
  • 7Laeis P,Piichler K,Kirch W.The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction[J].J Hypertens Sup- pl, 2001,19( 1 ) : S21-S32.
  • 8Schwocho LR,Masonson HN.Pharmacokinetics of CS- 866,a new angiotensin I1 receptor blocker,in healthy subjects[J].J Clin Pharmacol, 2001,41 (5) : 515-527.
  • 9von Bergmann K,Laeis P,Piichler K,et d.Olmesartan me- doxomil :influence of age,renal and hepatic function on the pharmacokinetics of olmesartan medoxomil[J].J Hyper- tens Supp1,2001,19( 1 ) : $33-$40.
  • 10Bolbrinker J,Huber M,Scholze J,et a/.Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects[J].Fundam Clin Phar- macol, 2009,23 (6) : 767-774.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部